Proprietary AI analyst is now available

Smith & Nephew Valuation Multiples

Discover Smith & Nephew's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Penumbra, Fisher & Paykel, Olympus, Medpace and more.

Smith & Nephew Overview

About Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.


Founded

1937

HQ

United Kingdom

Employees

17.3K

Financials (LTM)

Revenue: $6B
EBITDA: $2B

EV

$15B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Smith & Nephew Financials

Smith & Nephew reported last 12-month revenue of $6B and EBITDA of $2B.

In the same LTM period, Smith & Nephew generated $4B in gross profit, $2B in EBITDA, and $911M in net income.

Revenue (LTM)


Smith & Nephew P&L

In the most recent fiscal year, Smith & Nephew reported revenue of $6B and EBITDA of $2B.

Smith & Nephew is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 26%, and net margin of 14%.

See analyst estimates for Smith & Nephew
LTMLast FY202320242025202620272028
Revenue$6B$6B$6B$6B$6B
Gross Profit$4B$4B$4B$4B$4B
Gross Margin69%68%69%70%68%
EBITDA$2B$2B$956M$1B$2B
EBITDA Margin26%26%17%21%25%
EBIT Margin20%20%11%15%14%
Net Profit$911M$884M$263M$412M$625M
Net Margin14%14%5%7%10%
Net Debt-$3B---

Financial data powered by Morningstar, Inc.

Smith & Nephew Stock Performance

Smith & Nephew has current market cap of $13B, and enterprise value of $15B.

Market Cap Evolution


Smith & Nephew's stock price is $14.88.

Smith & Nephew share price decreased by 0.4% in the last 30 days, and increased by 0.1% in the last year.

Smith & Nephew has an EPS (earnings per share) of $1.04.

See more trading valuation data for Smith & Nephew
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$15B$13B1.4%-0.4%-7.5%0.1%$1.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Smith & Nephew Valuation Multiples

Smith & Nephew trades at 2.4x EV/Revenue multiple, and 9.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Smith & Nephew

EV / Revenue (LTM)


Smith & Nephew Financial Valuation Multiples

As of June 5, 2026, Smith & Nephew has market cap of $13B and EV of $15B.

Smith & Nephew has a P/E ratio of 13.9x.

LTMLast FY202320242025202620272028
EV/Revenue2.4x2.5x2.8x2.7x2.5x
EV/EBITDA9.3x9.7x16.1x12.6x10.1x
EV/EBIT12.4x12.8x24.9x17.9x18.0x
EV/Gross Profit3.5x3.7x4.0x3.8x3.7x
P/E13.9x14.3x48.1x30.7x20.2x
EV/FCF19.7x18.1x85.2x25.4x18.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Smith & Nephew Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Smith & Nephew Margins & Growth Rates

Smith & Nephew grew revenue by 7% and EBITDA by 9% in the last fiscal year.

In the most recent fiscal year, Smith & Nephew reported gross margin of 68%, EBITDA margin of 26%, and net margin of 14%.

See estimated margins and future growth rates for Smith & Nephew

Smith & Nephew Margins

Last FY202420252026202720282029
Gross Margin68%70%68%69%
EBITDA Margin26%21%25%26%
EBIT Margin20%15%14%20%
Net Margin14%7%10%14%
FCF Margin14%10%14%11%

Smith & Nephew Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%5%6%7%
Gross Profit Growth8%6%4%8%
EBITDA Growth9%28%25%13%
EBIT Growth7%39%(0%)51%
Net Profit Growth7%57%52%51%
FCF Growth(17%)235%41%(17%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Smith & Nephew Operational KPIs

Smith & Nephew's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Smith & Nephew's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Smith & Nephew's Rule of X is 43% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Smith & Nephew
LTMLast FY202320242025202620272028
Rule of 4032%33%---
Bessemer Rule of X42%43%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue-38%40%39%38%
G&A Expenses to Revenue42%44%7%6%7%
R&D Expenses to Revenue5%5%6%5%5%
Opex to Revenue-54%58%55%54%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Smith & Nephew Competitors

Smith & Nephew competitors include Penumbra, Fisher & Paykel, Olympus, Medpace, Cooper Companies, Align Technology, United Imaging, Zydus Lifesciences, Fresenius Medical Care and Coloplast.

Most Smith & Nephew public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Penumbra8.7x8.2x46.7x44.0x
Fisher & Paykel9.2x9.1x26.6x26.4x
Olympus2.1x2.0x9.0x11.7x
Medpace5.0x4.8x22.3x21.6x
Cooper Companies3.5x3.4x11.3x10.8x
Align Technology2.8x2.7x10.3x9.9x
United Imaging6.1x5.7x33.3x32.4x
Zydus Lifesciences4.2x4.1x13.5x15.8x

This data is available for Pro users. Sign up to see all Smith & Nephew competitors and their valuation data.

Start Free Trial

Acquisitions by Smith & Nephew

Smith & Nephew has acquired 14 companies to date.

Last acquisition by Smith & Nephew was on January 12th 2026. Smith & Nephew acquired Integrity Orthopaedics for $450M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Smith & Nephew

Integrity Orthopaedics
CartiHeal
Engage Surgical
Integra LifeSciences (extremity orthopaedics unit)
Description
Integrity Orthopaedics is a developer of soft tissue repair devices for rotator cuff surgeries. Based in Texas, the company markets the Integrity Anchor, a suture system providing 1,500N knot strength and biologic coatings to reduce re-tear rates by 25%. FDA-cleared in 2022, it deploys in 200 ORs nationwide with broad fixation across tendon footprints.
CartiHeal is a Herzliya-headquartered medical device company pioneering cartilage regeneration implants. The Agili-C scaffold, implanted arthroscopically, promotes hyaline cartilage formation in knee defects without cells or growth factors. FDA-approved in 2023 following pivotal trials showing superiority over microfracture in 261 patients.
Engage Surgical is a Salt Lake City-based orthopedics firm owning the only FDA-cleared cementless unicompartmental knee system in the US market. The Engage Partial Knee features a titanium plasma spray coating for biological fixation, used in medial and lateral compartment replacements. Surgeons implant it via minimally invasive techniques, with clinical data showing 98% survivorship at five years. Launched in 2019, the system addresses wear issues in cemented alternatives for active patients.
Integra LifeSciences Extremity Orthopaedics unit is a Plainsboro, New Jersey-based division developing orthopedic implants and instruments for foot, ankle, hand, and wrist procedures. The portfolio features the Puregenvi collagen matrix for tendon protection and the Infuse bone graft system. Its R&D pipeline advances a next-generation shoulder replacement system alongside extremity reconstruction devices. The unit supplies hospitals and surgery centers throughout North America and Europe.
HQ CountryUnited StatesIsraelUnited StatesUnited States
HQ City
Minneapolis, MN
Kfar Saba
Orlando, FL
Plainsboro, NJ
Deal Date12 Jan 202622 Nov 202319 Jan 202229 Sep 2020
Valuation$450M$330M$135M$240M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Smith & Nephew acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Smith & Nephew

Smith & Nephew has invested in 4 companies to date.

Latest investment by Smith & Nephew was on January 25th 2023. Smith & Nephew invested in Miach Orthopaedics in their $30M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Smith & Nephew

Miach Orthopaedics
Trice Medical
Trice Medical
OrthoSpace
Description
Miach Orthopaedics is a Westborough-headquartered medical device company founded in 2016 developing the Bridge-Enhanced ACL Repair implant. This bio-engineered scaffold promotes native tissue regeneration as an alternative to autografts for anterior cruciate ligament injuries.
Trice Medical is a Pennsylvania-based developer of camera-enabled orthopedic diagnostic devices including the SeeTrue needle and miin system for in-office visualization of joints and tissues. Founded in 2011, the company equips physicians with single-use, integrated tools that deliver immediate imaging, reducing reliance on MRI and lowering procedure costs for patients with musculoskeletal conditions.
Trice Medical is a Pennsylvania-based developer of camera-enabled orthopedic diagnostic devices including the SeeTrue needle and miin system for in-office visualization of joints and tissues. Founded in 2011, the company equips physicians with single-use, integrated tools that deliver immediate imaging, reducing reliance on MRI and lowering procedure costs for patients with musculoskeletal conditions.
-
HQ CountryUnited StatesUnited StatesUnited StatesIsrael
HQ City
Boston, MA
Philadelphia, PA
Philadelphia, PA
-
Deal Date25 Jan 202314 Jan 20196 Jun 20171 Dec 2016
RoundSeries BSeries CSeries CSeries A
Raised$30M$18M$19M$7M
InvestorsAmzak Health Investors; DSM Venturing; Endeavour Vision; NFL Players Association; Sectoral Asset Management; Smith & NephewBioStar Capital; Charter Capital Partners; HealthQuest Capital; Municipal Employee Retirement System; Safeguard Scientifics; Smith & NephewBioStar Capital; HealthQuest Capital; Safeguard Scientifics; Smith & NephewHealthpointCapital; Johnson & Johnson Robotics and Digital Solutions; Smith & Nephew; Triventures
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Smith & Nephew investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Smith & Nephew

When was Smith & Nephew founded?Smith & Nephew was founded in 1937.
Where is Smith & Nephew headquartered?Smith & Nephew is headquartered in United Kingdom.
How many employees does Smith & Nephew have?As of today, Smith & Nephew has over 17K employees.
Who is the CEO of Smith & Nephew?Smith & Nephew's CEO is Deepak S. Nath.
Is Smith & Nephew publicly listed?Yes, Smith & Nephew is a public company listed on London Stock Exchange.
What is the stock symbol of Smith & Nephew?Smith & Nephew trades under SN. ticker.
When did Smith & Nephew go public?Smith & Nephew went public in 1951.
Who are competitors of Smith & Nephew?Smith & Nephew main competitors include Penumbra, Fisher & Paykel, Olympus, Medpace, Cooper Companies, Align Technology, United Imaging, Zydus Lifesciences, Fresenius Medical Care, Coloplast.
What is the current market cap of Smith & Nephew?Smith & Nephew's current market cap is $13B.
What is the current revenue of Smith & Nephew?Smith & Nephew's last 12 months revenue is $6B.
What is the current revenue growth of Smith & Nephew?Smith & Nephew revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Smith & Nephew?Current revenue multiple of Smith & Nephew is 2.4x.
What is the current EBITDA of Smith & Nephew?Smith & Nephew's last 12 months EBITDA is $2B.
What is Smith & Nephew's EBITDA margin?Smith & Nephew's last 12 months EBITDA margin is 26%.
What is the current EV/EBITDA multiple of Smith & Nephew?Current EBITDA multiple of Smith & Nephew is 9.3x.
What is the current FCF of Smith & Nephew?Smith & Nephew's last 12 months FCF is $784M.
What is Smith & Nephew's FCF margin?Smith & Nephew's last 12 months FCF margin is 12%.
What is the current EV/FCF multiple of Smith & Nephew?Current FCF multiple of Smith & Nephew is 19.7x.
How many companies Smith & Nephew has acquired to date?As of June 2026, Smith & Nephew has acquired 14 companies.
What was the largest acquisition by Smith & Nephew?$2B acquisition of Arthrocare on 3rd February 2014 was the largest M&A Smith & Nephew has done to date.
What companies Smith & Nephew acquired?Smith & Nephew acquired Arthrocare, Osiris Therapeutics, Integrity Orthopaedics, CartiHeal, Blue Belt Technologies, Integra LifeSciences (extremity orthopaedics unit), Rotation Medical, Tusker Medical, Engage Surgical, Leaf Healthcare, and 4 other companies.
In how many companies Smith & Nephew has invested to date?As of June 2026, Smith & Nephew has invested in 4 companies.
What was the last Smith & Nephew investment?On 25th January 2023 Smith & Nephew invested in Miach Orthopaedics, participating in a $30M Series B round, alongside Amzak Health Investors, DSM Venturing, Endeavour Vision, NFL Players Association, and Sectoral Asset Management.
In what companies Smith & Nephew invested in?Smith & Nephew invested in Miach Orthopaedics, Trice Medical, OrthoSpace, and Michelson Diagnostics.

See public comps similar to Smith & Nephew

Lists including Smith & Nephew

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial